Life threatening neuroleptic malignant syndrome due to olanzapine;Lebensbedrohliches malignes neuroleptisches syndrom unter olanzapin

Psychiatrische Praxis

Volumn 30, Issue 5, 2003, Pages 279-282

  Kopf, Andrea ^a   Köster, Johannes ^a   Schulz, Andreas ^a   Krömker, Horst ^b   Becker, Thomas ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Psychiatrische Abteilung   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; ELECTROCONVULSIVE THERAPY; FEMALE; FREQUENCY ANALYSIS; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOSIS; REMISSION; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; ELECTROCONVULSIVE THERAPY; FEMALE; HALOPERIDOL; HUMANS; INTENSIVE CARE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PIRENZEPINE; PSYCHOTIC DISORDERS; RECURRENCE;

EID: 0042530500     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40681     Document Type: Article

References (29)

1. Aboraya A, Schumacher J, Abdalla E, Le Page J, McGhee M, Butcher D, Griffin H, Shahda M. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. The West Virginia Medical Journal 2002; 98: 63-65
2. Apple JE, Hauer G. Neuroleptic malignant syndrome associated with olanzapine. Psychosomatics 1999; 40, 3: 267-268
3. Burkhard PR, Vingerhoets FJG. Olanzapine-induced neuroleptic malignant syndrome. Arch Gen Psychiatry 1999; 56: 101-102
4. Filice GA, Mc Dougall BC, Ercan-Fang N, Billington CJ. Neuroleptic malignant syndrome associated with olanzapine. The Annals of Pharmacotherapy 1998; 32: 1158-1159
5. Gheorghiu S, Knobler HY, Drumer D. Recurrence of neuroleptic malignant syndrome with olanzapine treatment. Am J Psychiatry 1999; 156: 1836
6. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155: 1113-1116
7. Järventausta K, Leinonen E. Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand 2000; 102: 231-233
8. Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Australian and New Zealand Journal of Psychiatry 1998; 32: 884-886
9. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999; 33: 623-630
10. Marcus EL, Vass A, Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy. The Annals of Pharmacotherapy 1999; 33: 697-699
11. Margolese H, Chouinard G. Olanzapine-induced neuroleptic malignant syndrome with mental retardation. Am J Psychiatry 1999; 156: 1115-1116
12. Moltz DA, Coeytaux RR. Case Report. Possible neuroleptic malignant syndrome associated with olanzapine. J Clin Psychopharmacol 1998; 18: 485-486
13. Nyfort-Hansen K, Alderman CP. Possible neuroleptic malignant syndrome associated with olanzapine. The Annals of Pharmacotherapy 2000; 34: 667
14. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatric Services 1998; 49: 1163-1172
15. Philibert RA, Adam LA, Frank FM et al. Olanzapine usage associated with neuroleptic malignant syndrome. Psychosomatics 2001; 42: 528-529
16. Reeves RR, Torres RA, Liberto V, Hart RH. Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy 2002; 22: 641-644
17. Sierra-Biddle D, Herran A, Diez-Aja S, Gonzales-Mata JM, Vidal E, Diez-Manrique F, Vázquez-Barquero JL. Neuroleptic malignant syndrome and olanzapine. J Clin Psychopharm 2000; 20: 704-705
18. Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. The Journal of Emergency Medicine 2000; 19: 355-357
19. Tsai G, Crisostomo G, Rosenblatt M, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Annals of Clinical Psychiatry 1995; 7: 91-96
20. Weller M, Kornhuber J. Clozapin: Risikoneuroleptikum für die Auslösung eines malignen neuroleptischen Syndroms (MNS) oder neuroleptische Alternative bei positiver MNS-Anamnese. Fortschr Neurol Psychiat 1993; 61: 217-222
21. Assion HJ, Heinemann F, Laux G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci 1998; 248: 231-239
22. Bhana N, Perry CM. Olanzapine. A review of its use in the treatment of bipolar I disorder. CNS Drugs 2001; 15: 871-904
23. Garcia G, Ghani S, Poveda RA, Dansky BL. Neuroleptic malignant syndrome with antidepressant/antipsychotic drug combination. The Annals of Pharmacotherapy 2001; 35: 784-785
24. Harradine PG, Williams SE, Doherty SR. Neuroleptic malignant syndrome: an underdiagnosed condition. MJA 2001; 174: 593-594
25. Heinemann F, Assion HJ, Laux G. Malignes neuroleptisches Syndrom unter der Behandlung mit Antidepressiva. Fortschr Neurol Psychiat 1997; 65: 208-213
26. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever. Arch Gen Psychiatry 1986; 43: 839-842
27. Shalev A, Munitz H. The Neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337-347
28. Pope HG, Keck PE, Mcelroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143: 1227-1233
29. Reddig S, Minnema AM, Tandon R. Neuroleptic malignant syndrome and clozapine. Annals of Clinical Psychiatry 1993; 5: 25-27